Royal Bank of Canada reiterated their outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a research report report published on Monday morning,Benzinga reports. Royal Bank of Canada currently has a $68.00 price target on the stock.
Several other research analysts also recently commented on the stock. JMP Securities reiterated a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $63.00 price objective on the stock. Evercore ISI restated an "outperform" rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $73.38.
Get Our Latest Research Report on Jasper Therapeutics
Jasper Therapeutics Stock Performance
Shares of NASDAQ JSPR traded up $0.55 during mid-day trading on Monday, reaching $22.12. 206,668 shares of the company traded hands, compared to its average volume of 175,848. The company's fifty day moving average is $21.63 and its two-hundred day moving average is $20.69. Jasper Therapeutics has a fifty-two week low of $5.02 and a fifty-two week high of $31.01. The stock has a market cap of $331.82 million, a PE ratio of -4.67 and a beta of 2.18.
Institutional Investors Weigh In On Jasper Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new position in shares of Jasper Therapeutics during the 2nd quarter worth about $740,000. Rhumbline Advisers acquired a new stake in Jasper Therapeutics during the second quarter valued at approximately $300,000. American Century Companies Inc. grew its stake in shares of Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock valued at $322,000 after purchasing an additional 3,032 shares during the period. Wolff Wiese Magana LLC bought a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $59,000. Finally, Fernwood Investment Management LLC boosted its stake in Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock valued at $995,000 after buying an additional 3,427 shares in the last quarter. Institutional investors own 79.85% of the company's stock.
Jasper Therapeutics Company Profile
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Articles
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.